Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients
Open Access
- 2 December 2021
- journal article
- research article
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 130 (06) , 358-367
Abstract
Purpose We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic. Patients and Methods Seventy-eight non-diabetic patients were randomly selected and beinaglutide or metformin was administered for 12 weeks. The primary endpoints were changes in body weight and the proportions of patients who lost≥5 and≥10% of their baseline body weights. Results A total of 64 patients completed the study; patients in the beinaglutide group exhibited more bodyweight loss than those in the metformin group [(9.5±0.8%; 9.1±0.9 kg) and (5.1±0.9%; 4.5±0.8 kg), respectively, corresponding to a difference of approximately 4.5 kg (95% confidence interval, 2.2–6.9 kg; P<0.01)]. In the beinaglutide group, 90.6 and 40.6% of the patients lost≥5 and≥10% of their body weight, respectively, whereas, in the metformin group, these rates were 46.9 and 12.5%, respectively (P<0.01 and P<0.05). Weight loss following beinaglutide treatment mainly resulted from the loss of fat mass. Compared to metformin, beinaglutide induced a greater decrease in the body mass index, weight circumference, percent body fat, and body fat mass (total, trunk, limb, android, and gynoid). Additionally, beinaglutide decreased serum insulin levels and ameliorated insulin resistance. Conclusions Beinaglutide is more efficient than metformin at reducing weight and fat mass in patients who are overweight/obese and non-diabetic. Beinaglutide may be a useful therapeutic option for overweight/obesity control in the Chinese population.Keywords
Funding Information
- National Natural Science Foundation of China (81970704)
- National Natural Science Foundation of China (81970689)
- National Natural Science Foundation of China (81900787)
- National Natural Science Foundation of China (81800752)
- National Natural Science Foundation of China (81800719)
- National Key Research and Development Program of China (2016YFC1304804)
- National Key Research and Development Program of China (2017YFC1309605)
- Jiangsu Provincial Key Medical Discipline (ZDXKB2016012)
- Key Project of Nanjing Clinical Medical Science, Key Research and Development Program of Jiangsu Province of China (BE2015604)
- Key Project of Nanjing Clinical Medical Science, Key Research and Development Program of Jiangsu Province of China (BE2016606)
- Medical and Health Research Projects of Nanjing in Jiangsu Province of China (YKK18067)
- Project of Standardised Diagnosis and Treatment of Key Diseases in Jiangsu Province of China (2015604)
- Natural Science Foundation of Jiangsu Province of China (BK20201115)
- Drum Tower Hospital
This publication has 33 references indexed in Scilit:
- Uric Acid Secretion from Adipose Tissue and Its Increase in ObesityJournal of Biological Chemistry, 2013
- Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with ObesityExperimental and Clinical Endocrinology & Diabetes, 2012
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitusNature Reviews Endocrinology, 2012
- Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trialsBMJ, 2012
- Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissueDiabetes, Obesity and Metabolism, 2009
- Role of Metformin for Weight Management in Patients Without Type 2 DiabetesAnnals of Pharmacotherapy, 2008
- Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 yearsCurrent Medical Research and Opinion, 2007
- Mechanisms of action of glucagon-like peptide 1 in the pancreasPharmacology & Therapeutics, 2007
- The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesityInternational Journal of Obesity, 2001
- Overweight, Obesity, and Blood Pressure: The Effects of Modest Weight ReductionObesity Research, 2000